First Horizon Advisors’s Marker Therapeutics MRKR Stock Holding History

First Horizon Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12	Closed	–	–	2367
2021 Q3	$0	Buy	+12	New	+$246	﹤0.01%	2374

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

First Horizon Advisors's MRKR Position: Q4 2021 in Review

First Horizon Advisors sold out of Marker Therapeutics (MRKR) in Q4 2021, closing a stake of 12 shares.

First Horizon Advisors first reported a position in MRKR in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 64 funds tracked by Wall St. Rank hold MRKR as of Q4 2021.

First Horizon Advisors reported no remaining Marker Therapeutics position as of Q4 2021 after selling out during the quarter.
First Horizon Advisors sold 12 Marker Therapeutics shares in Q4 2021.
First Horizon Advisors first reported a position in Marker Therapeutics in Q3 2021 and held it in 1 quarter.
First Horizon Advisors's Marker Therapeutics position peaked at $0 in Q3 2021.
64 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2021.

Based on First Horizon Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.